Key Findings:  This review of the current data (preclinical and clinical) supports that endocannabinoids pay a role in Autism spectrum disorder (ASD), and that cannabidiol (CBD) may provide therapeutic uses in the treatment of symptoms and comorbidities associated with ASD.
Type of Study:  Meta-analysis
Study Result:  Positive
Study Location(s):  Brazil
Year of Pub:  2022
Cannabinoids Studied:  Cannabidiol (CBD), Endocannabinoid (unspecified)
Phytocannabinoid Source:  Unspecified
Chemotype:  Chemotype III